

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934** for the quarterly period ended March 31, 2009

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934** for the transition period from _____ to _____

Commission file number 000-15303

HST GLOBAL, INC.

(Exact name of registrant as specified in its charter)

<u>Nevada</u> (State or other jurisdiction of incorporation or organization)	<u>73-1215433</u> (I. R. S. Employer Identification No.)
<u>150 Research Drive, Hampton, VA</u> (Address of principal executive offices)	<u>23666</u> (Zip Code)

Issuer's telephone number 757-766-6100

<u>n/a</u> (Former name, former address and former fiscal year, if changed since last report)
--

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).
Yes ☐ No ☒

The number of shares of the registrant's common stock outstanding as of March 31, 2009 was 24,966,053 shares.

HST GLOBAL, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

<u>PART I. FINANCIAL INFORMATION</u>	<u>Page No.</u>
Item 1. Condensed Consolidated Interim Financial Statements (Unaudited)	
Condensed Consolidated Balance Sheets at March 31, 2009 (unaudited).....	F-3
Condensed Consolidated Statements of Operations for the three months ended March 31, 2009 (Unaudited).....	F-4
Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2009 (Unaudited).....	F-5
Notes to Condensed Consolidated Interim Financial Statements (unaudited).....	F-6
Item 2. Management’s Discussion and Analysis.....	10
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	11
Item 4. Controls and Procedures.....	11
 <u>PART II. OTHER INFORMATION</u>	
Item 1. Legal Proceedings.....	12
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.....	12
Item 3. Defaults Upon Senior Securities	13
Item 4. Submission of Matters to a Vote of Security Holders	13
Item 5. Other Information	13
Item 6. Exhibits	13
Signatures	14

PART I. FINANCIAL INFORMATION.

ITEM 1 – CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

HST GLOBAL, INC. AND SUBSIDIARIES
(Formerly Health Source Technologies, Inc.)
(a Development Stage Company)
CONDENSED CONSOLIDATED BALANCE SHEET
March 31, 2009
(unaudited)

	March 31, 2009 (Unaudited)	December 31, 2008
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ -	\$ 776
Property, plant and equipment, net of accumulated depreciation	2,190	2,433
TOTAL ASSETS	\$ 2,190	\$ 3,210
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	\$ 192,659	\$ 50,865
Deposits - Shareholder	250,000	250,000
Advances from Shareholder	83,310	2,010
Note payable - related party	100,000	100,000
Total Current Liabilities	\$ 625,969	\$ 402,875
STOCKHOLDERS' EQUITY (DEFICIENCY):		
Preferred stock; 5,000,000 shares authorized; \$.001 par value; 1,000,000 shares issued and none outstanding	-	-
Capital stock, \$.001 par value; 100,000,000 shares authorized; 24,966,053 shares issued and outstanding at March 31, 2009;	24,967	24,887
Additional paid-in capital	1,290,565	1,190,646
Deficit accumulated during the development stage	(1,939,311)	(1,615,198)
Total Stockholders' Equity (Deficiency)	\$ (623,779)	\$ (399,665)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)	\$ 2,190	\$ 3,210

The notes are an integral part of these financial statements

HST GLOBAL, INC. AND SUBSIDIARIES
(Formerly Health Source Technologies, Inc.)
(a Development Stage Company)
CONSOLIDATED STATEMENT OF OPERATIONS
Three Months Ended March 31, 2009
(unaudited)

	Three Months Ended March 31, 2009 (Unaudited)	Three Months Ended March 31, 2008 (Unaudited)	From Date of Inception (8/6/07) to March 31, 2009 (Unaudited)
REVENUES	\$ -	\$ -	\$ -
COST OF SALES	-	-	-
GROSS PROFIT	\$ -	\$ -	\$ -
OPERATING EXPENSES:			
Selling and distribution expenses	\$ -	\$ -	\$ -
Salaries	9,692	8,077	112,338
Consulting	205,731	65,000	1,041,058
General and administrative expenses	108,690	46,418	746,787
TOTAL OPERATING EXPENSES	\$ 324,113	\$ 119,495	\$ 1,900,183
NET (LOSS)	\$ (324,113)	\$ (119,495)	\$ (1,900,183)
NET INCOME (LOSS) PER SHARE: BASIC AND DILUTED - COMMON	\$ (0.01)	\$ (0.00)	
WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED - COMMON	24,932,720	24,031,853	

The notes are an integral part of these financial statements

HST GLOBAL, INC. AND SUBSIDIARIES
(Formerly Health Source Technologies, Inc.)
(a Development Stage Company)
CONSOLIDATED STATEMENT OF CASH FLOWS
Three Months Ended March 31, 2009
(unaudited)

	Three Months Ended March 31, 2009 (Unaudited)	Three Months Ended March 31, 2008 (Unaudited)	From Date of Inception (August 6, 2007) to March 31, 2009 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income (loss)	\$ (324,113)	\$ (119,495)	\$ (1,900,183)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	243	-	727
Common stock issued for services	-	-	142,500
Changes in operations-assets and liabilities net of acquisitions:			
Accounts payable and accrued expenses	141,794	77,820	192,659
Note payable	-	-	100,000
Tax payable	-	346	-
Total Adjustments	\$ 142,037	\$ 78,166	\$ 435,886
Net Cash used in Operating Activities	\$ (182,076)	\$ (41,329)	\$ (1,464,297)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchase of equipment	-	-	(2,917)
Acquisition cost	-	(25,000)	-
Net Cash used in Investing Activities	\$ -	\$ (25,000)	\$ (2,917)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from sale of common stock	100,000	-	1,150,500
Deposits from shareholders	-	-	250,000
Advances from shareholders	81,300	-	83,310
Effect of merger adjustment	-	-	(16,596)
Proceeds from loans	-	252,560	-
Net cash provided by financing activities	181,300	252,560	1,467,214
Net Increase (decrease) in cash	\$ (776)	\$ 186,231	\$ -
CASH AT BEGINNING PERIOD	\$ 776	\$ (985)	\$ -
CASH AT END OF PERIOD	\$ -	\$ 187,216	\$ -

The notes are an integral part of these financial statements

HST GLOBAL, INC. AND SUBSIDIARIES
(Formerly Health Source Technologies, Inc.)
(a Development Stage Company)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2009

NOTE 1 - BASIS OF PRESENTATION

The consolidated financial statements of HST Global, Inc. and subsidiaries (the "Company") have been prepared in accordance with generally accepted accounting principles for financial information and pursuant to the requirements for reporting on Form 10-QSB and Item 310(b) of Regulation S-B. Accordingly they do not include all the information and footnotes required by accounting principles generally accepted in the United States of American for complete financial statements. However, such information reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The consolidated balance sheet information as of March 31, 2009 was derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2008. These annual financial statements should be read in conjunction with that report.

The consolidated financial statements include the accounts of the Company and Health Source Technologies, Inc (a wholly owned subsidiary).

NOTE 2 - NATURE AND PURPOSE OF BUSINESS

HST Global, Inc. (the Company) was incorporated under the laws of the state of Nevada on August 6, 2007. The company is currently headquartered in Hampton, Virginia. HST Global, Inc. is an Integrated Health and Wellness company that is developing and / or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

The company has identified the growing acceptance of alternative cancer treatments worldwide which has placed us in a perfect position to open our own brand of Cancer Treatment Centers. This strategy will enable the company to address the challenges individuals face in the treatment of cancer in the later stages.

NOTE 3 - NATURE OF SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS

The company considers all highly liquid debt instruments purchased with maturity of three months or less to be cash equivalents.

REVENUE RECOGNITION

The company considers revenue to be recognized at the time the service is performed.

USE OF ESTIMATES

The preparation of the Company's financial statements required management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company's short-term financial instruments consist of cash and cash equivalents and accounts payable. The carrying amounts of these financial instruments approximate fair value because of their short-term maturities. Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash. During the year the Company did not maintain cash deposits at financial institution in excess of the \$100,000 limit covered by the Federal Deposit Insurance Corporation. The Company does not hold or issue financial instruments for trading purposes nor does it hold or issue interest rate or leverage derivative financial instruments.

EARNINGS PER SHARE

Basic Earnings per Share ("EPS") is computed by dividing net income available to common stockholders by the weighted average number of common stock shares outstanding during the year. Diluted EPS is computed by dividing net income available to common stockholders by the weighted-average number of common stock shares outstanding during the year plus potential dilutive instruments such as stock options and warrants. The effect of stock options on diluted EPS is determined through the application of the treasury exercises are hypothetically used to repurchase the Company's common stock at the average market price during the period. Loss per share is unchanged on a diluted basis since the assumed exercise of common stock equivalents would have an anti-dilutive effect.

INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes as required by SFAS No. 109 "Accounting for Income Taxes". SFAS 109 requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of certain assets and liabilities. Deferred income tax assets and liabilities are computed annually for the difference between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.

Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of the assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company had no significant deferred tax items arise during any of the period presented.

CONCENTRATION OF CREDIT RISK

The Company does not have any concentration of related financial credit risk.

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect that the adoption of other recent accounting pronouncements will have a material impact to its financial statements.

NOTE 4 - REVERSE MERGER, ACQUISITION AND BUSINESS DISPOSAL

On May 9, 2008, the Company entered into a merger and share exchange agreement with NT Holding Corp. NT Holding Corp was incorporated on April 11, 1984 under the laws of the State of Delaware. NT Holding Corp since its inception has been involved in various business operations including mining and the development of mineral properties. At the time of the merger and share exchange agreement, NT Holding had disposed of its operation assets and previous operations and was considered a development stage company.

This business acquisition has been accounted for as a reverse merger (recapitalization) with Health Source Technologies, Inc. deemed to be the accounting acquirer and NT Holding Corp deemed to be the legal acquirer. Accordingly, the historical financial information statements presented herein are those of Health Source Technologies, Inc. The accumulated deficit of the accounting acquirer has been carried forward after the acquisition as well as its assets and liabilities. Operations prior to the business combination are those of the acquirer. In conjunction with this business combination, the Board of Directors approved a 25 for 1 reverse split of the Company's common stock. The stock splits have been applied retroactively in the financial statements as if the split had occurred at the inception of the company.

NOTE 5 - STOCKHOLDERS EQUITY

The Company completed a business combination with Health Source Technologies Inc. on May 9, 2008 (see Note 4). In conjunction with this acquisition the Board of Directors approved a 25 for 1 reverse split of the Company's common stock. Prior to the acquisition the Company had 30,039,203 shares of common stock outstanding. The issuance of the 66,000,000 new shares of common stock to facilitate the business combination gave the company a total of 96,039,203 shares outstanding immediately before the stock split. After the stock split there were 4,041,568 shares outstanding. In addition, the post-acquisition equity structure was to reflect a 95% ownership by the shareholders of Health Source Technologies, Inc. In order to facilitate this structure, an additional 99,744,800 pre-split shares were issued and delivered to HST shareholders once sufficient authorized capital was available. On December 31, 2008, 3,989,792 post split shares were issued. On December 31, 2008, 3,989,792 post split shares were issued to Ron Howell, an officer and shareholder of the Company and Eric Clemons, a shareholder of the Company to complete the terms of the acquisition agreement. These shares have been retroactively reported in the financial statements as being issued in conjunction with the acquisition that occurred on May 5, 2008.

As part of the consideration for this business combination there were also 1,000,000 shares of preferred stock issued which were convertible into 16.2 (post split) shares of the company's common stock. These preferred shares were converted into 16,200,000 shares of common stock.

The Company has received \$1,049,000 from various persons and companies as deposits that were being held by the company in the anticipation of fulfilling a common stock subscription agreement. On August 20, 2008 the Company issued 839,200 shares of its common stock at a purchase price of \$1.25 per share. Also, on August 20, 2008 the company issued 15,000 shares of common stock in exchange for legal services rendered to the company. The shares were valued at \$9.50 per share which was the trading price of the shares on the date the shares were issued.

On October 28, 2008, the company received \$250,000 from an investor for working capital. This investor has agreed to receive 125,000 shares, at a price of \$1.25 per share. This transaction has been reported as Deposits from stockholders on the Company's Financial Statements

On February 20, 2009, the company received \$75,000 from an investor for working capital. This investor was issued 60,000 shares, at a price of \$1.25 per share. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On March 16, 2009, the company received \$25,000 from an investor for working capital. This investor was issued 20,000 shares, at a price of \$1.25 per share. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

NOTE 6 - FINANCIAL CONDITION AND GOING CONCERN

The Company's financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred a net loss from continuing operations of \$324,113 for the three months ended March 31, 2009 and has an accumulated deficit of \$1,939,311 at March 31, 2009. These factors raise substantial doubt as to its ability to obtain debt and/or equity financing and achieve profitable operations.

There are no assurances that HSTC will be able to either (1) achieve a level of revenues adequate to generate sufficient cash flow from operations; or (2) obtain additional financing through either private placement, public offerings and/or bank financing necessary to support its working capital requirements. To the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to HSTC. If adequate working capital is not available HSTC may be required to curtail its operations.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the condensed consolidated financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management's Discussion and Analysis set forth in (1) the Company's Annual Report on Form 10-KSB for the year ended December 31, 2008, as amended (which is also incorporated by reference herein) and (2) Quarterly Report on Form 10-QSB for the three months ended March 31, 2009.

As used in this report, the terms "Company", "we", "our", "us" and "HSTC" refer to HST Global, Inc.

PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "HSTC believes," "management believes" and similar language. The forward-looking statements are based on the current expectations of HSTC and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report. The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

Investors are also advised to refer to the information in our filings with the Securities and Exchange Commission, especially on Forms 10-KSB, 10-QSB and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

RESULTS OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2009 AS COMPARED TO THREE MONTHS ENDED MARCH 31, 2008

REVENUES, COST OF SALES AND OPERATING EXPENSES

The Company had revenues of \$0 for the quarter ended March 31, 2009 as compared to \$0 for the quarter ended March 31, 2008. The costs of sales for the same period were \$0 in 2009 as compared to \$0 for

2008. The Company incurred expenses of \$324,113 for the quarter ended March 2009 as compared to \$119,495 for the quarter ended March 2008. The expenses in the first quarter of 2009 were incurred to reorganize the Company and continue the company's strategic plan of opening wellness clinics worldwide. Until the Company obtains capital required to develop any properties or businesses and obtains the revenues needed from its future operations to meet its obligations, the Company will be dependent upon sources other than operating revenues to meet its operating and capital needs. Operating revenues may never satisfy these needs.

GAIN ON DISCONTINUED OPERATIONS

No income or loss was recorded in the current quarter from discontinued operations or from the disposal of a subsidiary.

LIQUIDITY AND CAPITAL RESOURCES

CASH

Our cash balance as of March 31, 2009 was \$0.

The Company does not currently have sufficient capital in its accounts, nor sufficient firm commitments for capital to assure its ability to meet its current obligations or to continue its planned operations. The Company is continuing to pursue working capital and additional revenue through the seeking of the capital it needs to carry on its planned operations. There is no assurance that any of the planned activities will be successful.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None.

ITEM 4. CONTROLS AND PROCEDURES.

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our Chief Executive Officer and Chief Financial Officer (collectively the "Certifying Officers") maintain a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management timely. Under the supervision and with the participation of management, the Certifying Officers evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule [13a-14(c)/15d-14(c)] under the Exchange Act) within 90 days prior to the filing date of this report. Based upon that evaluation, the Certifying Officers concluded that our disclosure controls and procedures are not effective in timely alerting them to material information relative to our company required to be disclosed in our periodic filings with the SEC.

CHANGES IN INTERNAL CONTROLS

In the Company's second amendment to its Annual Report on Form 10-K for the year ended December 31, 2007, our Certifying Officers had reported that as of December 31, 2007, there were multiple material weaknesses in the Company's internal control over financial reporting. These material weaknesses related to the fact that the Company's principal executive officer and principal financial officer were the same person, and that the Company had no additional personnel responsible for the review and control of financial information.

During the nine months ended September 30, 2008, the Company acquired a new operating business and as a result came under new management. The Company's new management set up new controls and procedures designed to ensure reliable financial reporting. The Company separated the primary duties of financial reporting control between its Chief Executive Officer and Chief Financial Officer, hired additional personnel with responsibilities that include review of financial records and transactions, and established procedures designed to ensure that every material transaction is properly recorded.

Nevertheless, our certifying officers have concluded that further changes will be necessary in order to remove these material weaknesses. Once sufficient operating capital is in place, we intend to hire additional personnel to enable us to initiate effective controls and procedures.

PART II: OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

None.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On March 16, 2009, the company received \$25,000 from an investor for working capital. This investor was issued 20,000 shares, at a price of \$1.25 per share. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On February 20, 2009, the company received \$75,000 from an investor for working capital. This investor was issued 60,000 shares, at a price of \$1.25 per share. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On December 31, 2008, the Company issued 1,994,896 shares of common stock to Ronald Howell as part of the consideration for the Acquisition of Health Source Technologies, Inc. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On December 31, 2008, the Company issued 1,994,896 shares of common stock to Eric Clemons as part of the consideration for the Acquisition of Health Source Technologies, Inc. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On October 28, 2008, the company received \$250,000 from an investor for working capital. This investor will receive 125,000 shares, at a price of \$1.25 per share.

On August 20, 2008, the Company issued 839,200 shares to 22 investors as subscriptions to a private offering, at a price of \$1.25 per share. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On August 20, 2008, the Company issued 15,000 shares for legal services. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On May 9, 2008, the Company issued 4,200,000 shares on the conversion of certain debt. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On May 9, 2008, the Company issued 66,000,000 shares of common stock to Health Source Technologies, Inc. as part of the consideration for the Acquisition of Health Source Technologies, Inc. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

On May 7, 2008, the Company issued 1,000,000 shares of Series A Preferred Stock to Health Source Technologies, Inc. as part of the consideration for the Acquisition of Health Source Technologies, Inc. Following the effective date of the one for twenty five reverse split, all of these shares were converted into 16,200,000 shares of common stock. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5 - OTHER INFORMATION

None.

ITEM 6 – EXHIBITS

The following exhibits are filed as part of this quarterly report on Form 10-QSB:

- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Acting Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Acting Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 15, 2009

HST GLOBAL, INC.
(the registrant)

By: \s\ Ron Howell
Ron Howell
Chief Executive Officer

CERTIFICATIONS

I, Ron Howell certify that:

1. I have reviewed this Report on Form 10-Q of HST Global, Inc. (the "Company") for the period ending March 31, 2009;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (c) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's Board of Directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

Date: May 15, 2009

/s/ Ron Howell
Ron Howell
Chief Executive Officer and Chairman

CERTIFICATIONS

I, Wes Tate, certify that:

1. I have reviewed this Report on Form 10-Q of HST Global, Inc. (the "Company") for the period ending March 31, 2009;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (c) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's Board of Directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

Date: May 15, 2009

/s/ Wesley D. Tate

Wesley D. Tate
Chief Financial Officer

**CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. 1350)**

In connection with the Report of HST Global, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Howell, Chief Executive Officer and Chairman of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), that to my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2009

\s\ Ron Howell
Ron Howell
Chief Executive Officer and Chairman

**CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. 1350)**

In connection with the Report of HST Global, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wesley D. Tate, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), that to my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2009

/s/ Wesley D. Tate
Wesley D. Tate
Chief Financial Officer